Evolent Health, Inc. (NYSE:EVH) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Evolent Health, Inc. (NYSE:EVH) have been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $42.00.

EVH has been the subject of several research analyst reports. Stephens restated an “overweight” rating and set a $42.00 price target on shares of Evolent Health in a research note on Tuesday, July 30th. Canaccord Genuity Group decreased their price target on shares of Evolent Health from $44.00 to $41.00 and set a “buy” rating for the company in a research note on Friday, May 10th. JMP Securities decreased their price target on shares of Evolent Health from $38.00 to $34.00 and set a “market outperform” rating for the company in a research note on Friday, May 10th. Finally, Citigroup began coverage on shares of Evolent Health in a research note on Monday, April 22nd. They issued a “buy” rating and a $40.00 price objective for the company.

Evolent Health Price Performance

Evolent Health stock opened at $22.58 on Monday. Evolent Health has a 52 week low of $17.98 and a 52 week high of $35.00. The company’s 50 day moving average price is $21.39 and its two-hundred day moving average price is $26.97. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.57. The stock has a market cap of $2.62 billion, a P/E ratio of -18.06 and a beta of 1.54.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, May 9th. The technology company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.04. Evolent Health had a negative net margin of 5.07% and a positive return on equity of 6.90%. The company had revenue of $639.65 million during the quarter, compared to analyst estimates of $601.60 million. On average, equities analysts predict that Evolent Health will post 0.9 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in EVH. ICA Group Wealth Management LLC purchased a new position in shares of Evolent Health during the 4th quarter valued at $33,000. Headlands Technologies LLC purchased a new position in shares of Evolent Health during the 1st quarter valued at $46,000. Signaturefd LLC grew its position in shares of Evolent Health by 1,470.7% during the 4th quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock valued at $48,000 after purchasing an additional 1,353 shares in the last quarter. NBC Securities Inc. purchased a new position in shares of Evolent Health during the 4th quarter valued at $69,000. Finally, Banque Cantonale Vaudoise purchased a new position in shares of Evolent Health during the 1st quarter valued at $88,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.